Nevirapine 50mg disp. tabs/PAC-30 gb

General Description
Nevirapine 50mg dispersible tablets, bottle pack of 30
(gb = generic / bottle pack)

Technical Specifications
Each dispersible tablet contains Nevirapine 50mg calculated on the anhydrous basis.
The tablets are used to prepare an oral suspension.

Therapeutic class
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Standard shelf life
24 Months

Other available formulations
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use
For more details, please see WHO treatment guidelines www.who.int/hiv/pub/guidelines/en/index.html and WHO Essential Medicines Library www.who.int/emlib/ or your regional/national guidelines.

Details about paediatric dosage schemes can be found at www.who.int/hiv/topics/paediatric/en/index.html

WHO generic tool for assessing paediatric ARV dosing
http://www.who.int/hiv/paediatric/generictool/en/

Indications
Management of HIV infection in combination with at least two other antiretroviral drugs. By mouth (oral), PO.
Prevention of mother-to-child transmission in HIV-infected patients

Storage
Do not store above 30ºC (86ºF).
Store in a tightly closed container
Keep out of reach and sight of children.

Dispensing instructions
Dispense in original container. Do not repack
Tablets are to be dispersed in about 5ml water immediately before administration

Regulatory Status
For latest updates check the list of Prequalified Medicines on the WHO website Prequalification Programme. apps.who.int/prequal/

For latest updates check the list of USFDA approved and tentatively approved items on the USFDA website. www.fda.gov/default.htm, www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/